CardioDx Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CardioDx Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3330
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CardioDx Inc (CardioDx) is a cardiovascular genomic diagnostics company. It undertakes the development of clinically validated tests in the areas of coronary artery disease, cardiac arrhythmias and heart failure. The company’s flagship product, Corus CAD gene expression test is used for assessing obstructive CAD (Coronary Artery Disease) in patients with chest pain. The company, along with its leading cardiologist’s conducts DISCERN (diagnostic investigation of sudden cardiac event risk) multi-center clinical study in the area of cardiac arrhythmias; and PREDICT trial to develop and validate gene expression tests for patients with symptoms suggestive of coronary artery disease. CardioDx is headquartered in Palo Alto, California, the US.

CardioDx Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CardioDx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CardioDx Inc, Medical Devices Deals, 2012 to YTD 2018 9
CardioDx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CardioDx Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CardioDx Raises Additional USD7.3 Million in Series D Financing Round 11
CardioDx Raises USD5 Million in Series D Financing Round 12
CardioDx Raises USD14 Million in Extended Series DD Venture Financing 13
CardioDx Secures USD6 Million in Venture Funding 14
CardioDx Inc – Key Competitors 15
CardioDx Inc – Key Employees 16
CardioDx Inc – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
CardioDx Inc, Pharmaceuticals & Healthcare, Key Facts 2
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CardioDx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CardioDx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
CardioDx Inc, Medical Devices Deals, 2012 to YTD 2018 9
CardioDx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CardioDx Raises Additional USD7.3 Million in Series D Financing Round 11
CardioDx Raises USD5 Million in Series D Financing Round 12
CardioDx Raises USD14 Million in Extended Series DD Venture Financing 13
CardioDx Secures USD6 Million in Venture Funding 14
CardioDx Inc, Key Competitors 15
CardioDx Inc, Key Employees 16

List of Figures
CardioDx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CardioDx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CardioDx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CardioDx Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[CardioDx Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Icici Bank Ltd
    Icici Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Icici Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • TUV Rheinland AG:企業の戦略的SWOT分析
    TUV Rheinland AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Advantage Oil & Gas Ltd. (AAV)-石油・ガス分野:企業M&A・提携分析
    Summary Advantage Oil & Gas Ltd. (Advantage Oil) is an upstream company that exploits, develops, acquires, and produces natural gas and liquids in Alberta. Its exploitation and development program is focused at Glacier. The company’s acreage is spread throughout the Western Canadian Sedimentary Basi …
  • EnergyAustralia Pty Ltd:電力:M&Aディール及び事業提携情報
    Summary EnergyAustralia Pty Ltd (EnergyAustralia), formerly TRUenergy, is an electric utility that invests in energy generation and retailing activities. The company generates electricity and retails power and gas. It produces electricity from coal, gas, solar and wind sources. EnergyAustralia offer …
  • Pan American Silver Corp:企業の戦略・SWOT・財務情報
    Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report Summary Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Elizabeth Arden, Inc. (RDEN):企業の財務・戦略的SWOT分析
    Elizabeth Arden, Inc. (RDEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Delcath Systems Inc (DCTH):製薬・医療:M&Aディール及び事業提携情報
    Summary Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloods …
  • DCP Midstream LLC-石油・ガス分野:企業M&A・提携分析
    Summary DCP Midstream, LLC (DCP Midstream), a joint venture between Spectra Energy and Phillips 66, gathers, processes, transports, stores and markets natural gas and natural gas liquids. It undertakes fractionation, transportation, marketing and trading natural gas liquids. The company also owns th …
  • Raiffeisen Group:企業の戦略・SWOT・財務情報
    Raiffeisen Group - Strategy, SWOT and Corporate Finance Report Summary Raiffeisen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Ausgrid-エネルギー分野:企業M&A・提携分析
    Summary Ausgrid is a state-owned electric corporation. It transmits, distributes, and retails electricity through transmission and distribution networks. The company also offers street lighting, tree trimming, combating graffiti, energy efficiency, installation and connection of small scale embedded …
  • Cielo Wind Power, LP:電力:M&Aディール及び事業提携情報
    Summary Cielo Wind Power, LP (Cielo Wind) is a wind power project development company. It designs, develops, owns and operates utility-grade wind power projects. The company provides a wide range of services including engineering, construction, operations and maintenance, land procurement, meteorolo …
  • Northfork Electric Cooperative, Inc.:発電所・企業SWOT分析
    Northfork Electric Cooperative, Inc. – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • GrafTech International Ltd:企業の戦略・SWOT・財務情報
    GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report Summary GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • PHOENIX Group:企業の戦略・SWOT・財務分析
    PHOENIX Group - Strategy, SWOT and Corporate Finance Report Summary PHOENIX Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Peter MacCallum Cancer Centre:製薬・医療:M&Aディール及び事業提携情報
    Summary Peter MacCallum Cancer Centre (Peter Mac) is a provider of public health services. It serves as a cancer research, treatment and education centre. The centre provides wide range of services including diagnostic, radiation therapy, treatment, cancer information and support services. It works …
  • F1 Oncology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary F1 Oncology Inc (F1 Oncology) is a developer of adoptive cellular therapy candidates. The company develops CAB technology to mitigate the on-target, off-tumor toxicity of Chimeric Antigen Receptor (CAR) T cell therapy. It is developing CAB technology. The company’s drugs are used in rewiring …
  • BioStar Pharmaceuticals Inc (BSPM):企業の財務・戦略的SWOT分析
    Summary BioStar Pharmaceuticals Inc (BioStar) is a developer, manufacturer and marketer of pharmaceutical and healthcare supplement products for various diseases and conditions. The company offers products such as huangyangning tablets, hyperthyroidism capsules, danshen granule, aoxing oleanolic aci …
  • Zoo Digital Group plc (ZOO):企業の財務・戦略的SWOT分析
    Summary Zoo Digital Group Plc (ZOO) is a technology company that offers localization and media production services. The company offers services such as subtitling, captioning, dubbing and digital distribution. Its activities include providing a range of services to allow television and movie content …
  • Human Longevity Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Human Longevity Inc (HLI) is a genomics-based technology company that develops sequenced genomes and phenotypic database. The company’s discovery capabilities include streamlining drug development, rescuing and repurposing drugs from failed clinical trials and discovery of biomarker and comp …
  • Zagro Asia Ltd:企業の戦略的SWOT分析
    Zagro Asia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆